Table 1.
Target gene | Delivery system | Administration | Ref. |
TNF-α siRNA therapy with delivery system | |||
TNF-α | TKN | Oral | [14] |
TNF-α | PEI-PVA | Oral | [15] |
TNF-α | NiMOS | Oral | [16] |
TNF-α | OMe-P | Oral | [17] |
TNF-α | TPP-PPM | Ex vivo | [18] |
TNF-α | Fab'-bearing PLA-PEG | Oral | [19] |
siRNA therapy targeting other molecules with delivery system | |||
CyD1 | Abs to β7 integrin | Intravenous | [22] |
TNF-α/CyD1 | NiMOS | Oral | [23] |
Map4k4 | β1,3-D-glucan shell | Oral | [24] |
CD98 | scCD98-functionalized | Oral | [25] |
SiRNA: Small interfering RNA; TKN: Thioketal nanoparticle; PEI-PVA: Polyethyleneimine/polyvinyl alcohol; NiMOS: Nanoparticles-in-microspheres oral system; OMe-P: 2’-O-methyl and propanediol modification; TPP-PPM: Mannosylated bioreducible cationic polymer/sodium triphosphate; Fab'-bearing PLA-PEG: Polylactic acid-polyethylene glycol copolymer/Fab' portion of the F4/80 Ab; scCD98-functionalized: Chitosan-alginate hydrogel/single-chain CD98 Abs.